Gilead Sciences

Open: 78.8 Close: 78.62 Change: -0.18

The unbelievably easy way to evaluate Gilead Sciences Company Inc: Use an AI.

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on February 6, 2024. Company raises stake in cancer-centric Arcus Biosciences. Michael Okunewitch has given his Buy rating.

Today's News

Gilead Sciences is expediting production of its Yescarta and shortening the therapys overall turnaround time. Kite, the Kite logo, Yescarta, GILEAD are trademarks. Gilead Sciences on linkedin: Its been 10 years since gileads curative therapies began impacting the lives of people living with hepatitis C. Gileads and Arcus announce amended collaboration and equity investment. Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024. Company raises stake in cancer-centric Arcus Biosciences. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases. The core of its portfolio is HIV and hepatitis B and C. Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Gileads future prospects. Gilead invests $320M in Arcus, expands stake to 33% (NYSE:RCUS) Arcus Biosciences shares jumped 16% in post-market trading Monday following news that partner Gileads has increased its stake in the compa. Gilead Sciences, Inc. has on average historically risen by 23.8% based on the past 31 years of stock performance. Over the next 52 weeks, the company has risen higher in 22 of those 31 years over the subsequent 52-week period. Average price target for Gilead Sciences comes to $89.50.50. Average price of $115.00 is 46.27% Upside. Average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell) Gilead Sciences has made a $320m equity investment in Arcus Biosciences and appointed its chief commercial officer Johanna Mercier to the Arcus Board. The amended collaboration also includes governance enhancements that enable simplified decision-making.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

Are looking for the most relevant information about Gilead Sciences? Investor spend a lot of time searching for information to make investment decisions in Gilead Sciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, Arcus, therapy, year, Gileads, stake, and the most common words in the summary are: gilead, science, stock, job, inc, company, gild, . One of the sentences in the summary was: Michael Okunewitch has given his Buy rating.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #job #inc #company #gild.